CustomSurg, provider of data-driven, end-to-end solutions for faster surgeries on complex bone fractures, has obtained an undisclosed amount in its funding round led by US East Coast Fund CHMBR Partners LLC. The funds will be used to accelerate the FDA regulatory application process and launch the first-in-human study and establish its presence in the US market.
Approximately 25% of surgeries following complex bone fractures lead to patients experiencing complications and enduring long-term disabilities. Despite advancements in implants enhancing fracture stabilization, treatment choices remain subjective, often relying on significant intraoperative experimentation for complex fractures. Uncertainty surrounding the stability of a specific fracture construct results in patients being immobilized for as long as three months post-surgery.
Thomas Zumbrunn, Arvind von Keudell (medical lead) and co-founder), and Valentin Splett (commercial lead), founded CustomSurg in 2019, proposing a new approach to this challenge, starting with knee-joint surgeries. They devised a service model that provides a fully-customized solution for a personalized treatment strategy based on patient-specific, biomechanical data. The startup’s technology uses a CT scan to generate 3D models and mimic daily activities through real-life load simulations, allowing for personalized surgical planning and operative implementation, and patient-specific implant design. By quantifying the stability of a specific fracture construct, patients can expedite their recovery process. Surgeons on the other hand benefit from precise pre-operative planning and real-time guidance during surgery using 3D-printed bone models and augmented reality assistance.
Supported by a team of ten people, the ETH Spinoff has obtained fresh funds from an investment consortium led by US East Coast fund manager CHMBR Partners LLC. The round also includes German-based HTGF | High-Tech Gründerfonds, Switzerland-based kickfund and and several international Medtech investors. The funds provide the startup the required resources to grow the team, invest in further clinical research, and obtain regulatory clearance to bring AI-guided trauma surgery to clinicians and patients around the globe. The startup plans to enter the US market upon obtaining approval from the US Food and Drug Administration.
(RAN)
Please login or sign up to comment.
Commenting guidelines